IMCR
Immunocore Holdings Ltd
NASDAQ: IMCR · HEALTHCARE · BIOTECHNOLOGY
$28.85
-1.63% today
Updated 2026-06-05
Market cap
$1.47B
P/E ratio
—
P/S ratio
3.57x
EPS (TTM)
$-0.56
Dividend yield
—
52W range
$28 – $41
Volume
0.4M
WallStSmart proprietary scores
42
out of 100
Grade: D
Sell
Investment rating
8.7
Growth
A7.0
Quality
B+3.0
Profitability
D5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
0.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$63.49
+120.07%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy10 Buy4 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 13.60% QoQ
+ Debt/equity 0.11x — low leverage
Risks
- Altman Z 0.36 — distress zone
- Thin margins at -6.68%
- Negative free cash flow $-15.53M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $144.23M | $197.39M | $247.98M | $297.57M | $412.81M |
| Net income | $-43.46M | $-43.75M | $-40.81M | $-26.42M | $12.97M |
| EPS | — | — | — | — | $-0.56 |
| Free cash flow | $-51.41M | $-1.97M | $20.89M | $-11.20M | $-15.53M |
| Profit margin | -30.13% | -22.17% | -16.45% | -8.88% | -6.68% |
Peer comparison
Smart narrative
Immunocore Holdings Ltd trades at $28.85. Our Smart Value Score of 42/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 0.36, it sits in the distress. TTM revenue stands at $412.81M. with profit margins at -6.68%.
Frequently asked questions
What is Immunocore Holdings Ltd's stock price?
Immunocore Holdings Ltd (IMCR) trades at $28.85, on a P/S of 3.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Immunocore Holdings Ltd overvalued?
Immunocore Holdings Ltd carries a Smart Value Score of 42/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Immunocore Holdings Ltd (IMCR)?
The 12-month analyst consensus target is $63.49, about 120.1% above the current $28.85. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Immunocore Holdings Ltd's revenue?
Immunocore Holdings Ltd's trailing twelve-month revenue is $412.81M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Immunocore Holdings Ltd's Altman Z-Score is 0.36, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio3.57x
ROE-7.14%
Beta0.75
50D MA$29.55
200D MA$32.84
Shares out0.05B
Float0.04B
Short ratio—
Avg volume0.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—